Eris Lifesciences (BOM:540596) Long-Term Debt : ₹6,545 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Long-Term Debt?

Eris Lifesciences's Long-Term Debt for the quarter that ended in Mar. 2024 was ₹6,545 Mil.

Eris Lifesciences's quarterly Long-Term Debt declined from Sep. 2023 (₹5,970 Mil) to Dec. 2023 (₹0 Mil) but then increased from Dec. 2023 (₹0 Mil) to Mar. 2024 (₹6,545 Mil).

Eris Lifesciences's annual Long-Term Debt increased from Mar. 2022 (₹450 Mil) to Mar. 2023 (₹6,444 Mil) and increased from Mar. 2023 (₹6,444 Mil) to Mar. 2024 (₹6,545 Mil).

Eris Lifesciences Long-Term Debt Historical Data

The historical data trend for Eris Lifesciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Long-Term Debt Chart

Eris Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Long-Term Debt

Get a 7-Day Free Trial

450.00

6,444.47

6,545.07

Eris Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															6,444.47	-	5,970.38	-	6,545.07

Eris Lifesciences (BOM:540596) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Eris Lifesciences Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Eris Lifesciences (BOM:540596) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Long-Term Debt

Traded in Other Exchanges

ERIS:India

Address

Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054

Website

https://www.eris.co.in

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines